I reject the idea that a man who keeps every prostate cancer surveillance appointment has ‘untreated cancer,’” writes Howard ...
PSMA PET/CT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone in men with ...
Researchers have developed and validated a 45-gene transcriptomic signature, Met-Score, that quantifies metastatic competence ...
A real-world clinical validation of a commercial AI system for prostate MRI found high sensitivity for clinically significant ...
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging. Melbourne (Australia) and Indianapolis, IN (United States) \| September 30, 2026. FDA Fast T ...
“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.
Veracyte, Inc. announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology ...
A phase III trial ancillary analysis found the Decipher Prostate Test predicts which intermediate-risk prostate cancer ...
There is a moment in a prostate cancer consultation when I sometimes wish I could slow time down. The patient has already been through the blood test, the scan and ...
(Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 ...
A 67-year-old male patient initially presented with a PSA of 12. He ultimately underwent a prostate needle biopsy, with 3/8 ...
Everyday Health on MSN
Understanding prostate cancer survival rates
Learn what prostate cancer survival rates say about treatment effectiveness and life expectancy, and the importance of early detection through screening.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results